Table 2 Clinical characteristics of the sample (n = 92)
From: Validity and reliability of the Portuguese version of the modified Migraine Disability Assessment
Variable | Value | N | % |
|---|---|---|---|
Age of migraine diagnosis (years) | Min-max | 2–76 | |
Mean ± standard deviation | 31.2 ± 14.7 | ||
< 20 | 27 | 29.3 | |
21–39 | 39 | 42.4 | |
≥ 40 | 26 | 28.3 | |
Time on consultation (years) | Min-max | 0–37 | |
Mean ± standard deviation | 3.8 ± 5.6 | ||
< 1 | 36 | 39.2 | |
1–3 | 27 | 29.3 | |
≥ 4 | 29 | 31.5 | |
Frequency of headaches in previous month | Min-max | 0–30 | |
Mean ± standard deviation | 8.9 ± 4.5 | ||
Prophylactic treatment | Now, continued | 41 | 49.4 |
Now, not previously | 17 | 20.5 | |
Not now, but previously yes | 18 | 21.7 | |
Never | 7 | 8.4 | |
Previous prophylactic treatment | Yes | 59 | 71.1 |
No | 24 | 28.9 | |
Drugs prescribed | Antiepileptic | 50 | 54.3 |
Antidepressant | 48 | 52.2 | |
Beta-Blockers | 34 | 36.9 | |
Botulinum Toxin A | 1 | 12.0 | |
Calcium Blockers | 7 | 7.6 | |
Non-Steroidal anti-Inflammatory | 4 | 1.4 | |
Neuromodulation Devices | 1 | 1.1 | |
Invasive Treatments | 1 | 1.1 | |
Other | 10 | 10.9 | |
Acute treatment for migraine | Yes | 89 | 97.8 |
No | 2 | 2.2 | |
Acute therapeutics usually followed | Analgesics | 84 | 91.3 |
Trypanoes | 44 | 47.8 | |
Antiemetics | 15 | 16.3 | |
Opioids | 6 | 6.5 | |
Ergotaminicos | 5 | 5.4 | |
Corticosteroids | 2 | 2.2 | |
Other | 1 | 1.1 | |
Other comorbidities | Yes | 18 | 20.9 |
No | 68 | 79.1 |